Table 4. Multivariate logistic regression model of factors impacting survival outcomes in the study population.
| Factors | 5 year RFS | |
|---|---|---|
| OR (95%CI) | P-value | |
| Multifocality | ||
| Yes vs No | 1.96(1.17-3.28) | 0.01 |
| Grading | ||
| 3 vs 1 - 2 | 2.26(1.36-3.75) | 0.002 |
| Stage | ||
| III vs I-II | 3.59(2.20-5.85) | <0.0001 |
| Hormonal therapy | ||
| No vs Yes | 2.88(1. 53-6.14) | 0.006 |
| aTrastuzumab therapy in ER≤50% | ||
| No vs Yes | 4.33 (1.78-10.55) | 0.001 |
| aTrastuzumab therapy in ER50 | ||
| No vs Yes | 1.16 (0.70-1.93) | 0.57 |
Abbreviations: CI, confidence interval; OR, Odds ratio; RFS, Relapse-Free Survival; ER50, TP tumors with ER staining in more than 50% tumor cells
a
ER*Trastuzumab therapy, pINTERACTION =0.01